First multicenter survey on infectious keratitis following excimer laser surgery in Japan
Takeshi Ide1, Daijiro Kurosaka2, Tadashi Senoo3, Shigeru Kinoshita4, Yuichi Ohashi5, Yoshitsugu Inoue6, Kazuo Tsubota7, LASIK Safety Network8
1 Minamiaoyama Eye Clinic; Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan
2 Department of Ophthalmology, Iwate Medical University, Iwate, Japan
3 Department of Ophthalmology, Dokkyo Medical University, Tochigi, Japan
4 Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
5 Department of Ophthalmology, Ehime University School of Medicine, Ehime, Japan
6 Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Tottori, Japan
7 Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan
Minamiaoyama Eye Clinic, Renai Aoyama Building 4F, 3-3-11, Kitaaoyama, Minato-ku, Tokyo 107-0061
Source of Support: None, Conflict of Interest: None
Purpose: To report the first multicenter survey in Japan on infectious keratitis after excimer laser surgery.
Methods: The laser in situ keratomileusis (LASIK) Safety Network (LSN) Committee sent questionnaires to 28 LSN member hospitals to assess the total number of laser corneal surgeries, the number of infection cases (including suspicious cases), and the postoperative follow-up rate during a 3-year period.
Results: Responses were obtained from 27 (96.4%) of 28 institutions. One phototherapeutic keratectomy infection case was reported among 22,415 excimer laser surgery cases, which equates to an incidence rate of 0.004%. The follow-up rate was 94.14% (67.2–100%), 80.11% (41.0–96.1%), 57.95% (11.5–93.0%), and 46.64% (4.7–93.0%) at 1 month, 3 months, 6 months, and 12 months of follow-up, respectively.
Conclusion: Infectious keratitis is a potentially devastating complication of excimer laser surgery. We did not see any infectious keratitis for refractive cases. This first multicenter survey in Japan on infectious keratitis provides important information on the safety of this therapy.